LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Home・Stock List・Amgen Inc

Amgen Inc

Open

Sector Healthcare

335.06 0.32

Buy Sell

Overview

Share price change

24h

Current

Min

333.03

Max

338.42

Key metrics
By Trading Economics
Income	-880M -113M
Sales	-746M 7.5B
P/E Sector Avg	22.76 79.786
EPS	3.96
Profit margin	-1.517
Employees	26,700
EBITDA	-1.5B 2.2B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	-3.7 downside

Dividends
By Dow Jones
Next Earnings	6 Aug 2024
Next Dividend date	6 Sept 2024
Next Ex Dividend date	15 Aug 2024

Market Stats
By TradingEconomics
Market Cap	12B 178B
Previous open	334.74
Previous close	335.06

News Sentiment

By Acuity

26%

74%

46 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

330.83 / 335.91 Support & Resistance

Amgen Inc Chart

Related News

2 May 2024, 20:42 UTC

Earnings

Amgen Posts Higher 1Q Revenue, Swings to Loss

6 Feb 2024, 21:48 UTC

Earnings

Amgen 4Q Revenue Surges as Acquisition Boosts Results

19 Jul 2024, 11:00 UTC

Peer Comparison

Price change

Amgen Inc Forecast

Price Target

By TipRanks

-3.7% downside

12 Months Forecast

Average 323.18 USD -3.7%

High 380 USD

Low 215 USD

Based on 21 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

21 ratings

Buy

Hold

Sell

Based on 21 analysts giving stock ratings to Amgen Inc - Dist in the past 3 months.

Technical Score

By Trading Central

330.83 / 335.91Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

46 / 369 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.